DK0526905T3 - Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem - Google Patents

Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem

Info

Publication number
DK0526905T3
DK0526905T3 DK92113463T DK92113463T DK0526905T3 DK 0526905 T3 DK0526905 T3 DK 0526905T3 DK 92113463 T DK92113463 T DK 92113463T DK 92113463 T DK92113463 T DK 92113463T DK 0526905 T3 DK0526905 T3 DK 0526905T3
Authority
DK
Denmark
Prior art keywords
multimers
soluble forms
preparation
pharmaceutical compositions
compositions containing
Prior art date
Application number
DK92113463T
Other languages
English (en)
Inventor
Cord Brakebusch
David Wallach
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11062796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0526905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0526905T3 publication Critical patent/DK0526905T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK92113463T 1991-08-07 1992-08-07 Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem DK0526905T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL99120A IL99120A0 (en) 1991-08-07 1991-08-07 Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
DK0526905T3 true DK0526905T3 (da) 2004-08-16

Family

ID=11062796

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92113463T DK0526905T3 (da) 1991-08-07 1992-08-07 Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem

Country Status (12)

Country Link
US (1) US5478925A (da)
EP (1) EP0526905B1 (da)
JP (1) JPH07145068A (da)
AT (1) ATE266724T1 (da)
AU (1) AU661008B2 (da)
CA (1) CA2075358C (da)
DE (1) DE69233351T2 (da)
DK (1) DK0526905T3 (da)
ES (1) ES2218518T3 (da)
IL (1) IL99120A0 (da)
PT (1) PT526905E (da)
ZA (1) ZA925904B (da)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
US6479632B1 (en) * 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
IL98078A0 (en) * 1991-05-07 1992-06-21 Yeda Res & Dev Pharmaceutical compositions comprising an anticytokyne
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) * 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
DE59010941D1 (de) * 1989-04-21 2005-03-24 Amgen Inc TNF-Rezeptor, TNF bindende Proteine und dafür kodierende DNAs
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc A method of producing a recombinant human necrotic factor absorber
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP0417563B1 (de) 1989-09-12 2000-07-05 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5919452A (en) * 1991-03-18 1999-07-06 New York University Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US5698195A (en) * 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
WO1993019777A1 (en) * 1992-03-30 1993-10-14 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US20050255104A1 (en) * 1993-01-29 2005-11-17 Centocor, Inc. Methods of treating psoriasis using anti-TNF receptor fusion proteins
CA2119089A1 (en) * 1993-03-29 1994-09-30 David Banner Tumor necrosis factor muteins
WO1995015179A1 (en) * 1993-12-01 1995-06-08 Unisearch Limited Method of treating intestinal disorders
NZ278607A (en) * 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
US5852173A (en) * 1994-10-19 1998-12-22 Genetics Institute, Inc. TNF receptor death ligand proteins and inhibitors of ligand binding
US5849501A (en) * 1994-10-19 1998-12-15 Genetics Institute, Inc. TNF receptor death domain ligand proteins and method to identify inhibitors of ligand binding
US5712381A (en) 1994-10-19 1998-01-27 Genetics Institute, Inc. MADD, a TNF receptor death domain ligand protein
US5847099A (en) * 1994-10-19 1998-12-08 Genetics Institute, Inc. TNF receptor death domain ligand proteins
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) * 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP1541689B1 (en) 1996-02-20 2012-09-05 Merck Serono SA Hybrid proteins which form heterodimers
CN1261579C (zh) * 1996-02-20 2006-06-28 应用研究系统Ars控股公司 形成异源二聚体的杂种蛋白质
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997034616A1 (en) * 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
ES2207759T3 (es) 1996-12-06 2004-06-01 Amgen Inc. Terapia de combinacion que utiliza una proteina de union del factor de necrosis tumoral (tnf) en el tratamiento de enfermedades inducidas por el tnf.
EP0951551B9 (en) 1996-12-23 2012-12-26 Immunex Corporation Ligand for receptor activator of nf-kappa b, ligand is member of tnf superfamily
US6455040B1 (en) * 1997-01-14 2002-09-24 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
US6433147B1 (en) * 1997-01-28 2002-08-13 Human Genome Sciences, Inc. Death domain containing receptor-4
US8329179B2 (en) * 1997-01-28 2012-12-11 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
AU6250098A (en) * 1997-01-28 1998-08-18 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US7452538B2 (en) 1997-01-28 2008-11-18 Human Genome Sciences, Inc. Death domain containing receptor 4 antibodies and methods
US6872568B1 (en) 1997-03-17 2005-03-29 Human Genome Sciences, Inc. Death domain containing receptor 5 antibodies
US20040136951A1 (en) * 1997-03-17 2004-07-15 Human Genome Sciences, Inc. Death domain containing receptor 5
US20080248046A1 (en) * 1997-03-17 2008-10-09 Human Genome Sciences, Inc. Death domain containing receptor 5
KR100527638B1 (ko) * 1997-03-17 2005-11-23 휴먼 게놈 사이언시즈, 인코포레이티드 사망 도메인을 보유하는 수용체 5
US20050233958A1 (en) * 1997-03-17 2005-10-20 Human Genome Sciences, Inc. Death domain containing receptor 5
NZ332995A (en) 1997-04-15 2000-07-28 Snow Brand Milk Products Co Ltd A protein which binds to osteoclastogenesis inhibitory factor (OCIF)
ES2284203T5 (es) 1997-04-16 2016-03-11 Amgen Inc. Proteínas de unión a osteoprotegerina y sus receptores
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
AU7469998A (en) * 1997-05-01 1998-11-24 Amgen, Inc. Chimeric opg polypeptides
US6187564B1 (en) * 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US6287558B1 (en) 1997-08-01 2001-09-11 Biohybrio Technologies Llc Devices containing cells or tissue and an agent that inhibits damage by a host cell molecule
US7704944B2 (en) * 1997-08-14 2010-04-27 Yeda Research And Development Company Ltd. Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis
DE69943022D1 (de) 1998-03-19 2011-01-20 Human Genome Sciences Rockville Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
US6893838B1 (en) 1998-04-07 2005-05-17 Genetics Institute Llc DADD, death activator death domain protein
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
JP4267233B2 (ja) * 1999-09-10 2009-05-27 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’チオホスホルアミデート：それらの合成および使用
AR025984A1 (es) * 1999-10-07 2002-12-26 Maxygen Aps Polipeptidos oligomericos de cadena simple
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001064889A2 (en) 2000-03-02 2001-09-07 Xencor Tnf-alpha variants for the treatment of tnf-alpha related disorders
US7662367B2 (en) * 2000-03-02 2010-02-16 Xencor, Inc. Pharmaceutical compositions for the treatment of TNF-α related disorders
US7056695B2 (en) 2000-03-02 2006-06-06 Xencor TNF-α variants
US7244823B2 (en) * 2000-03-02 2007-07-17 Xencor TNF-alpha variants proteins for the treatment of TNF-alpha related disorders
US7687461B2 (en) * 2000-03-02 2010-03-30 Xencor, Inc. Treatment of TNF-α related disorders with TNF-α variant proteins
US7446174B2 (en) 2001-03-02 2008-11-04 Xencor, Inc. Protein based TNF-α variants for the treatment of TNF-α related disorders
US20070172449A1 (en) * 2000-03-02 2007-07-26 Xencor, Inc. TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
EP2431054A3 (en) 2000-06-15 2013-03-06 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030228309A1 (en) * 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
EP1366058B1 (en) 2001-02-09 2011-01-26 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
CA2444632A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
AU2002309647C1 (en) * 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
DE60235989D1 (de) 2001-06-26 2010-05-27 Amgen Fremont Inc Antikörper gegen opgl
US6867189B2 (en) * 2001-07-26 2005-03-15 Genset S.A. Use of adipsin/complement factor D in the treatment of metabolic related disorders
TWI334439B (en) 2001-08-01 2010-12-11 Centocor Inc Anti-tnf antibodies, compositions, methods and uses
CA2471140A1 (en) * 2001-12-20 2003-07-03 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1497445A2 (en) * 2002-04-01 2005-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
PL375041A1 (en) 2002-04-05 2005-11-14 Amgen Inc. Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
MXPA05007019A (es) 2002-12-30 2005-08-18 Amgen Inc Terapia de combinacion con factores co-estimuladores.
MXPA05007615A (es) * 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
WO2004068928A2 (en) 2003-02-06 2004-08-19 Uutech Limited Bradykinin b2 receptor antagonist peptide from amphibian skin
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281799A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
CA2570261C (en) 2004-07-08 2014-06-10 Pneumrx, Inc. Pleural effusion treatment device, method and material
US7482124B2 (en) * 2005-07-08 2009-01-27 Bristol-Myers Squibb Company Method of identifying a PPARgamma-agonist compound having a decreased likelihood of inducing dose-dependent peripheral edema
US20070202512A1 (en) * 2005-08-19 2007-08-30 Bristol-Myers Squibb Company Human single nucleotide polymorphisms associated with dose-dependent weight gain and methods of use thereof
US20070086979A1 (en) 2005-10-13 2007-04-19 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
MX2009002756A (es) * 2006-09-12 2009-05-25 Cosmo Technologies Ltd Composiciones farmaceuticas para la administracion oral o rectal de sustancias proteinicas.
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
AR064500A1 (es) * 2006-12-22 2009-04-08 Dow Agrosciences Llc Vacunas del virus west nile (wnv) de plantas, vectores y secuencias optimizadas de codones de plantas
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
US8415291B2 (en) 2008-10-31 2013-04-09 Centocor Ortho Biotech Inc. Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
DK2512450T3 (da) 2009-12-15 2018-04-23 Ascendis Pharma Endocrinology Div A/S Tør væksthormonsammensætning, der er transient bundet til en polymerbærer
UA112288C2 (uk) 2010-01-15 2016-08-25 Кірін-Емджен, Інк. Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
US8853149B2 (en) 2010-03-19 2014-10-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Integrin interaction inhibitors for the treatment of cancer
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
EP3153521B1 (en) 2010-03-26 2019-09-04 Trustees of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
CN102219860B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 FGFR-Fc融合蛋白及其用途
CN102219859B (zh) 2011-05-20 2012-09-12 烟台荣昌生物工程有限公司 拮抗血管新生诱导因子的融合蛋白及其用途
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
US9381244B2 (en) 2012-09-07 2016-07-05 King's College London VISTA modulators for diagnosis and treatment of cancer
EP4043493A1 (en) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
EP3126392B1 (en) 2014-03-31 2019-09-11 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
AU2015274504B2 (en) 2014-06-11 2021-02-04 Kathy A. Green Use of VISTA agonists and antagonists to suppress or enhance humoral immunity
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
CN107405398A (zh) 2014-12-05 2017-11-28 伊穆奈克斯特股份有限公司 鉴定vsig8作为推定vista受体及其用以产生vista/vsig8激动剂和拮抗剂的用途
JP7026509B2 (ja) 2015-06-24 2022-02-28 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体およびフラグメント
RU2020143675A (ru) 2015-08-07 2021-05-26 ЭйЭлЭкс Онколоджи Инк. Конструкции, имеющие sirp-альфа домен или его вариант
BR102016018074A2 (pt) 2015-08-07 2021-11-16 ALX Oncology Inc. Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2019509993A (ja) 2016-02-12 2019-04-11 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ（ｂ７ｈ５）抗体
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
MX2019009377A (es) 2017-02-07 2019-12-11 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la espondilitis anquilosante activa.
CA3092320C (en) 2018-12-07 2023-09-19 Remegen Co., Ltd. Bifunctional angiogenesis inhibitor and use thereof
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
SG11202112733XA (en) 2019-05-31 2021-12-30 Alx Oncology Inc Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
ATE128184T1 (de) * 1989-12-13 1995-10-15 Yeda Res & Dev Expression des rekombinanten tumor-nekrosisfaktor-bindungsproteins i (tbp-i).

Also Published As

Publication number Publication date
EP0526905A3 (en) 1993-05-05
CA2075358A1 (en) 1993-02-08
AU661008B2 (en) 1995-07-13
EP0526905A2 (en) 1993-02-10
DE69233351T2 (de) 2005-05-04
DE69233351D1 (de) 2004-06-17
PT526905E (pt) 2004-09-30
CA2075358C (en) 2002-10-01
ATE266724T1 (de) 2004-05-15
AU2090992A (en) 1993-02-11
ZA925904B (en) 1993-03-25
IL99120A0 (en) 1992-07-15
EP0526905B1 (en) 2004-05-12
JPH07145068A (ja) 1995-06-06
US5478925A (en) 1995-12-26
ES2218518T3 (es) 2004-11-16

Similar Documents

Publication Publication Date Title
DK0526905T3 (da) Multimerer af TNF-receptorers oplöselige former, deres fremstilling og farmaceutiske præparater indeholdende dem
DK0392300T3 (da) Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner
DE3060342D1 (en) Triazine derivatives, their preparation and their use as stabilising agents for synthetic polymers
HK1006717A1 (en) Derivatives of amidinophenylalanine procedure for their preparation their utilisation and anticoagulant compositions comprising them
DK0555370T3 (da) Metoder og anvendelser for effektive, genetiske suppressorelementer
ES8707733A1 (es) Un procedimiento para la preparacion de triazolobenzodiazepinas
WO1992014696A3 (en) SUBSTITUTED α-AMINOALDEHYDES AND DERIVATIVES
DK0516588T3 (da) Substituerede diaminophthalimider og analoger
ATE28190T1 (de) Lichtschutzmittel fuer polymere.
DK0619806T3 (da) Fremstilling af substituerede piperidiner
TR26619A (tr) YENI BILESIKLER,BUNLARIN HAZIRLANMALARINA YÖNELIK ISLEMLER,BUNLARI ICEREN BILESIMLER VE BUNLARIN ZARARLI OT ÖLDüRüCüSü(HERBISIDAL) OLARAK KULLANI- MI.
DK39084A (da) 2-imino-pyrrolidiner, fremgangsmaade til deres fremstilling og terapeutiske midler indeholdende dem
DK0564358T3 (da) 3-aminochroman-spiro-derivater, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende sådanne
DK162923C (da) Farmaceutisk praeparat til inhibering af tumorcellevaekst og fremgangsmaade til fremstilling deraf
DK0552765T3 (da) benzimidazoler, farmaceutiske præparater indeholdende disse og fremgangsmåde til deres fremstilling
AU1998995A (en) Substituted fused and bridged bicyclic compounds as therapeutic agents
DE69229644D1 (de) 6H-Dibenz(c,e)(1,2)oxaphosphorin-6-oxid Derivative zur Stabilisierung von 3,4-Epoxycyclohexylmethyl(meth)acrylat
DK0418990T3 (da) 13-brom- og 13,14-dibrom-ergoliner, deres fremstilling og anvendelse i lægemidler
US5162542A (en) Substituted pyrazoline derivatives
IT8320095A0 (it) Etenil derivati di 1h-pirazolo aperta parentesi quadra 1,5-a chiusa parentesi quadra pirimidine sostituite e procedimento per laloro preparazione.
DK0427160T3 (da) Benzylselenobenzamid af aminopyridiner og picolylaminer
DK0582977T3 (da) Fremgangsmåde til fremstilling af 1,3-dialkyl-5-hydroxyoxindoler og etherderivater deraf
NO924190L (no) Fremgangsmaate for fremstilling av homogene, fine, pulverformige faststoffdispersjoner som eventuelt inneholder virksomme substanser
NO933465D0 (no) Legemidler inneholdende 1,5,6,7-tetrahydro -4- indazol -4- on-derivater, nye 1,5,6,7 - tetrahydro -4- indazol -4- on-derivater, og fremgangsmaate for deres fremstilling
DK551183A (da) Substituerede 9h-8-oxo-pyrimido(2,1-f)purin-2,4-dioner, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende forbindelserne